Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Cash from Operations: 2014-2024

Historic Cash from Operations for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to -$176.5 million.

  • Cidara Therapeutics' Cash from Operations fell 10.68% to -$40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$132.9 million, marking a year-over-year increase of 16.83%. This contributed to the annual value of -$176.5 million for FY2024, which is 686.97% down from last year.
  • Cidara Therapeutics' Cash from Operations amounted to -$176.5 million in FY2024, which was down 686.97% from -$22.4 million recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Cash from Operations peaked at -$22.4 million during FY2023, and registered a low of -$176.5 million during FY2024.
  • In the last 3 years, Cidara Therapeutics' Cash from Operations had a median value of -$28.5 million in 2022 and averaged -$75.8 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Cash from Operations skyrocketed by 53.63% in 2021, and later slumped by 686.97% in 2024.
  • Over the past 5 years, Cidara Therapeutics' Cash from Operations (Yearly) stood at -$54.4 million in 2020, then spiked by 53.63% to -$25.2 million in 2021, then decreased by 12.84% to -$28.5 million in 2022, then grew by 21.22% to -$22.4 million in 2023, then slumped by 686.97% to -$176.5 million in 2024.